顳骨鱗狀細胞癌之新輔助免疫檢查點抑制劑治療

// Neoadjuvant Immune Checkpoint Inhibitor Therapy in Temporal Bone Squamous Cell Carcinoma

23例侵犯顳骨鱗狀細胞癌接受術前免疫檢查點抑制劑（IO）｜26%完全緩解、17%部分（合43%）；皮膚原發約67%，9%免手術、9%手術降級｜應答者3年存活100% vs 78%，顯示IO可使選擇性病例手術降級，待第3期驗證

// This multi-institutional retrospective cohort of 23 patients evaluated neoadjuvant immune checkpoint inhibitor (IO) therapy for temporal bone–involving squamous cell carcinoma to inform neurotologic decision-making. Patients received neoadjuvant IO with radiologic (RECIST 1.1) and pathologic response assessment and subsequent surgical management as indicated. Overall 26% achieved complete response and 17% partial response (≈43% total responders), with higher response in cutaneous primaries (≈67%); about 9% avoided surgery and another 9% had less extensive operations. Responders had better 3‑year survival (100% vs 78% for progressive disease, P=0.029), suggesting neoadjuvant IO is a feasible option that can permit surgical de‑escalation in selected patients pending phase 3 trial data.

Published 2026年9月18日